Is massive scale proteomics causing a paradigm shift in biomarker discovery?
ABSTRACT
In this 45-minute talk, Dr. Stefánsson will discuss the largest population proteomics study ever performed to help provide more insight on disease and health outcomes. This collaborative research assembled expertise from deCODE Genetics and SomaLogic to combine the study of genetic and protein diversity to characterize disease biomarkers in the human population. The data from this type of proteomic study will inform drug discovery and development as well as improvements in health management. You will learn about:
- The high-throughput technologies that made this study possible
- The application of population proteomics in diagnosis and management of common and rare diseases
Dr. Kári Stefánsson
CEO, deCode Genetics
Kári Stefánsson is an Icelandic neurologist and founder and CEO of Reykjavik-based biopharmaceutical company deCODE genetics. In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome.
More webinars
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.
WebinarData Summit 2025
Take your research further with expert insights from the SomaScan™ Data Summit. Explore the latest platform updates, advanced data analysis tools, and innovative applications for SOMAmer™ reagents. From optimizing sample quality to customizing panels beyond 7K and 11K, this event is packed with knowledge to help you get the most from your data.